Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728468 · ClinicalTrials.gov registry record · Phase 1
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
A Phase 1 study of Advanced Malignant Solid Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT00728468 is a Phase 1 study of Advanced Malignant Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 16 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00728468, a Phase 1 study of Advanced Malignant Solid Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.
Conditions Studied
Interventions
- DRUG PF-00299804
Study Locations (2)
New York
- Roswell Park Cancer Institute - Buffalo
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728468
The ClinicalTrials.gov registry entry for NCT00728468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignant Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PF-00299804 is the first listed.
NCT00728468 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00728468 about?
NCT00728468 is a clinical study titled "A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients". Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, an...
What is the current status of trial NCT00728468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-09. Estimated completion is 2014-07.
What conditions does trial NCT00728468 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumors.
What interventions are being tested in trial NCT00728468?
The interventions under investigation include: PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT00728468?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00728468 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.